MX2017015574A - Inhibidores de tirosina quinasa de bruton. - Google Patents

Inhibidores de tirosina quinasa de bruton.

Info

Publication number
MX2017015574A
MX2017015574A MX2017015574A MX2017015574A MX2017015574A MX 2017015574 A MX2017015574 A MX 2017015574A MX 2017015574 A MX2017015574 A MX 2017015574A MX 2017015574 A MX2017015574 A MX 2017015574A MX 2017015574 A MX2017015574 A MX 2017015574A
Authority
MX
Mexico
Prior art keywords
inhibitors
bruton
tyrosine kinase
conditions
disclosed
Prior art date
Application number
MX2017015574A
Other languages
English (en)
Inventor
J Jia Zhaozhong
Chen Wei
Pozzan Alfonso
Babic Atallah Gordana
Francesco Raveglia Lucal
Zanaletti Riccardo
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of MX2017015574A publication Critical patent/MX2017015574A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Abstract

En la presente se describen inhibidores reversibles e irreversibles de la tirosina quinasa de Bruton (Btk). También se describen composiciones farmacéuticas que incluyen los compuestos. Se describen métodos de uso de los inhibidores de Btk, solos o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades o afecciones autoinmunitarias, enfermedades o afecciones heteroinmunitarias, cáncer, que incluye linfoma, y enfermedades o afecciones inflamatorias.
MX2017015574A 2015-06-02 2016-06-02 Inhibidores de tirosina quinasa de bruton. MX2017015574A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562169935P 2015-06-02 2015-06-02
US201562169941P 2015-06-02 2015-06-02
US201562169945P 2015-06-02 2015-06-02
US201562249340P 2015-11-01 2015-11-01
US201562249338P 2015-11-01 2015-11-01
US201562249336P 2015-11-01 2015-11-01
PCT/US2016/035489 WO2016196776A2 (en) 2015-06-02 2016-06-02 Inhibitors of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
MX2017015574A true MX2017015574A (es) 2018-08-09

Family

ID=57441893

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015574A MX2017015574A (es) 2015-06-02 2016-06-02 Inhibidores de tirosina quinasa de bruton.

Country Status (14)

Country Link
US (2) US20180305348A1 (es)
EP (1) EP3310776A4 (es)
JP (1) JP2018522823A (es)
KR (1) KR20180021740A (es)
CN (1) CN107709315A (es)
AU (2) AU2016270907B2 (es)
BR (1) BR112017025986A2 (es)
CA (1) CA2987054A1 (es)
IL (1) IL255831A (es)
MA (1) MA42623A (es)
MX (1) MX2017015574A (es)
RU (1) RU2017145650A (es)
SG (1) SG10201911523YA (es)
WO (1) WO2016196776A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10858364B2 (en) * 2016-12-21 2020-12-08 Acerta Pharma B.V. Imidazopyrazine inhibitors of Bruton's tyrosine kinase
KR101956815B1 (ko) * 2017-02-14 2019-03-12 한국화학연구원 트리아졸로피리다진 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
CN109384774B (zh) * 2017-08-11 2023-02-17 中国科学院上海药物研究所 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用
CN108530450B (zh) * 2018-05-03 2021-03-30 赖建智 具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用
WO2020018039A2 (en) 2018-05-25 2020-01-23 Banoglu Erden Highly potent tacc3 inhibitor as a novel anticancer drug candidate
EP3867242A1 (en) 2018-10-15 2021-08-25 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
EP3870579A4 (en) * 2018-10-22 2022-10-19 Alumis Inc. TYK2 INHIBITORS AND THEIR USES
EP3924350A1 (en) * 2019-02-13 2021-12-22 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
AU2020272937A1 (en) 2019-04-09 2021-10-21 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for Cbl-b inhibition, and use of a Cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
US11530229B2 (en) 2019-05-17 2022-12-20 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
KR20220026581A (ko) 2019-06-26 2022-03-04 누릭스 테라퓨틱스 인코포레이티드 Cbl-b 억제를 위한 치환된 벤질-트리아졸 화합물, 및 이의 추가의 용도
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
MX2022006672A (es) 2019-12-04 2022-08-08 Nurix Therapeutics Inc Compuestos bifuncionales para la degradacion de btk a traves de la via de proteosomas de ubiquitina.
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CA3179395A1 (en) * 2020-06-01 2021-12-09 Yuli Xie New pyrazine compound
WO2022071772A1 (ko) * 2020-09-29 2022-04-07 (주)메디톡스 단백질 키나제 저해제 및 그의 용도
CA3216541A1 (en) * 2021-04-12 2022-10-20 A2A Pharmaceuticals, Inc. Compositions and methods for treating cancer
CA3223769A1 (en) * 2021-07-01 2023-01-05 Xinglu ZHOU Bruton's tyrosine kinase and mutant degrader, composition and application thereof
WO2023088477A1 (zh) * 2021-11-22 2023-05-25 杭州和正医药有限公司 一种可降解btk激酶的多功能化合物、组合物及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4622047B2 (ja) * 1999-06-09 2011-02-02 アステラス製薬株式会社 新規なヘテロ環カルボキサミド誘導体
ATE288420T1 (de) * 1999-06-09 2005-02-15 Yamanouchi Pharma Co Ltd Neuartige heterocyclische carboxamid-derivate
JP2014005206A (ja) * 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
EP2762476A4 (en) * 2011-09-30 2015-03-25 Taiho Pharmaceutical Co Ltd 1,2,4-triazine-6-carboxamide derivative
WO2013052394A1 (en) * 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
IN2014CN04065A (es) * 2011-11-23 2015-09-04 Portola Pharm Inc
JP6109192B2 (ja) * 2012-01-10 2017-04-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピリダジンアミド化合物及びｓｙｋ阻害剤としてのそれらの使用
TWI532727B (zh) * 2012-01-17 2016-05-11 安斯泰來製藥股份有限公司 吡羧醯胺化合物
US9040530B2 (en) * 2012-06-22 2015-05-26 Portola Pharmaceuticals, Inc. 1,2,4-triazine-6-carboxamide kinase inhibitors
US20140113931A1 (en) * 2012-06-22 2014-04-24 Portola Pharmaceuticals, Inc. Substituted picolinamide kinase inhibitors
EP2964647A1 (en) * 2013-03-05 2016-01-13 F. Hoffmann-La Roche AG Inhibitors of bruton's tyrosine kinase
WO2014153280A1 (en) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
CN104262328B (zh) * 2013-09-18 2016-09-07 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
WO2015084998A1 (en) * 2013-12-05 2015-06-11 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase

Also Published As

Publication number Publication date
AU2016270907B2 (en) 2020-09-17
MA42623A (fr) 2018-06-20
RU2017145650A3 (es) 2019-11-22
AU2016270907A1 (en) 2017-12-07
WO2016196776A2 (en) 2016-12-08
WO2016196776A3 (en) 2017-01-05
JP2018522823A (ja) 2018-08-16
CA2987054A1 (en) 2016-12-08
US20180305348A1 (en) 2018-10-25
EP3310776A4 (en) 2019-01-16
CN107709315A (zh) 2018-02-16
AU2020286332A1 (en) 2021-01-21
BR112017025986A2 (pt) 2018-08-14
RU2017145650A (ru) 2019-07-15
IL255831A (en) 2018-01-31
SG10201911523YA (en) 2020-02-27
US20210070748A1 (en) 2021-03-11
KR20180021740A (ko) 2018-03-05
EP3310776A2 (en) 2018-04-25

Similar Documents

Publication Publication Date Title
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
PH12018502139A1 (en) Phosphaplatin liquid formulations
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
MX2017001512A (es) Compuestos activos hacia bromodominios.